news17 Oct 2013 22:22
" Lombard Medical Technologies PLC Thursday said that it has entered a new mutually beneficial licensing agreement with medical technology giant, Medtronic Incorporation.
The specialist medical device company, which focuses on the treatment of abdominal aortic aneurysms, said that it has been granted a non-exclusive license for US patent, which will now allow it to focus on launching its flagship product, Aorfix, which is an endovascular stent graft, commonly used to reinforce a weak spot in an artery.
As a result of the signed deal, Lombard Medical said that it has withdrawn its validity review request on the Jervis patent.
"The signing of this licensing agreement, the terms of which are advantageous to both parties, will allow Lombard Medical to focus our resources on the US launch of Aorfix," said Chief Executive Simon Hubbert in a statement.
Lombard Medical also said that it is experiencing growing sales in Europe, and anticipates regulatory approval for Aorfix in Japan in the first half of 2014.
It said that it plans to extend its facilities in Didcot in Oxfordshire, in order to meet increase demand.